A5048948956- Colorectal Cancer Treatments and Studies
- Colorectal and Anal Carcinomas
- Colorectal Cancer Surgical Treatments
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Gastrointestinal Tumor Research and Treatment
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Economic and Financial Impacts of Cancer
- Colorectal Cancer Screening and Detection
- Growth Hormone and Insulin-like Growth Factors
- Cancer, Lipids, and Metabolism
- Biosimilars and Bioanalytical Methods
- Genetic and Kidney Cyst Diseases
- Drug Transport and Resistance Mechanisms
- Multiple and Secondary Primary Cancers
- Cancer Diagnosis and Treatment
- Cancer Cells and Metastasis
- Immunotherapy and Immune Responses
Hospital Casa de Salud
2025
AstraZeneca (Brazil)
2024
Pfizer (United States)
2024
Bayer (United States)
2024
Merck (Germany)
2024
Pierre Fabre (Germany)
2024
Novartis (France)
2024
Roche (Switzerland)
2024
PharmaMar (Spain)
2024
Saint Louis University
2024
PURPOSE The optimal therapeutic sequence of the adjuvant chemotherapy component preoperative chemoradiotherapy (CRT) for patients with locally advanced rectal cancer is controversial. Induction before CRT may be associated better efficacy and compliance. PATIENTS AND METHODS A total 108 were randomly assigned to arm A-preoperative capecitabine, oxaliplatin, concurrent radiation followed by surgery four cycles postoperative capecitabine oxaliplatin (CAPOX)-or B-induction CAPOX surgery....
Abstract Purpose. The aim of this phase III trial was to compare the efficacy and safety bevacizumab alone with those capecitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy XELOX in first-line patients metastatic colorectal cancer (mCRC). Patients Methods. were randomly assigned receive six cycles bevacizumab, capecitabine, every 3 weeks followed by or until progression. primary endpoint progression-free survival (PFS) interval; secondary endpoints...
Total neoadjuvant treatment (TNT) is a valid strategy for patients with high-risk locally advanced rectal cancer (LARC). Biomarkers of response to TNT are an unmet clinical need. We aimed determine the value circulating tumor DNA (ctDNA) predict response, recurrence, and survival in LARC treated TNT.The GEMCAD 1402 was phase II randomized, multicentric trial that randomized 180 modified schedule fluorouracil, leucovorin, oxaliplatin (mFOLFOX6) +/- aflibercept, followed by chemoradiation...
PURPOSE EXONERATE (EXOsome and cell-free micro-RNAs of anti-EGFR ResistAnce) was an open-label, biomarker interventional study designed to develop, test, validate a liquid biopsy predictive progression-free survival (PFS), overall (OS), objective response rate (ORR) for first-line EGFR inhibitors in metastatic colorectal cancer (mCRC). PATIENTS AND METHODS Patients with newly diagnosed RAS-WT, chemotherapy-naïve mCRC, both right- left-sided, were enrolled 2-nationwide trials receive...
Abstract Background. The Maintenance in Colorectal Cancer trial was a phase III study to assess maintenance therapy with single-agent bevacizumab versus plus chemotherapy patients metastatic colorectal cancer. An ancillary conducted evaluate the circulating tumor cell (CTC) count as prognostic and/or predictive marker for efficacy endpoints. Patients and Methods. One hundred eighty were included. Blood samples obtained at baseline after three cycles. CTC enumeration carried out using...
// Teodoro Vargas 1 , Juan Moreno-Rubio 2, 3 Jesús Herranz 4 Paloma Cejas 5 Susana Molina Margarita González-Vallinas Marta Mendiola 2 Emilio Burgos 5, 6 Cristina Aguayo 7 Ana B. Custodio Isidro Machado 8 David Ramos 9 Meritxell Gironella 10 Isabel Espinosa-Salinas Ricardo 11 Roberto Martín-Hernández Alberto Risueño 12 Javier De Las Rivas Guillermo Reglero Yaya 13 Carlos Fernández-Martos Jorge Aparicio 14 Joan Maurel 15 Jaime Feliu Ramírez de Molecular Oncology, IMDEA-Food Institute, CEI...
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance common and constitutes main reason failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results largely deceiving. We analysed time to progression, overall survival, mutational status of RAS, BRAF nuclear p-IGF-1R expression by immunohistochemistry, 470 CRC patients. The effect...
Abstract Background. The need for preoperative chemoradiation or short-course radiation in all T3 rectal tumors is a controversial issue. A multicenter phase II trial was undertaken to evaluate the efficacy and safety of neoadjuvant capecitabine oxaliplatin combined with bevacizumab patients intermediate-risk adenocarcinoma. Methods. We recruited 46 adenocarcinoma selected by magnetic resonance imaging (MRI) who were candidates (R0) resection located middle third clear mesorectal fascia...
Abstract Background: Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, phase II, first-line, proof of concept study (NCT01303172), explored safety tolerability IMM-101 (heat-killed Mycobacterium obuense ; NCTC 13365) with gemcitabine (GEM) in advanced pancreatic ductal adenocarcinoma. Methods: Patients were randomised (2 : 1) to (10 mg ml −l intradermally)+GEM (1000 m −2 intravenously; n =75), or GEM alone ( =35). Safety was assessed on frequency incidence adverse...
Preclinical studies suggest that a vascular endothelial growth factor (VEGF) blockade may play role in the preoperative treatment of rectal adenocarcinoma; however, how to combine anti-VEGF drugs with neoadjuvant chemotherapy (CT) and/or chemoradiotherapy (CRT) remains controversial.To study effect aflibercept plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) induction CT prior standard CRT total mesorectal excision (TME) surgery patients high-risk adenocarcinoma.In Grupo...
<div>AbstractPurpose:<p>The EXOsome and cell-free miRNAs of anti-EGFR ResistAnce (EXONERATE) study was an open-label, biomarker interventional designed to develop, test, validate a liquid biopsy predictive progression-free survival (PFS), overall (OS), objective response rate (ORR) for first-line EGFR inhibitors in metastatic colorectal cancer (mCRC).</p>Patients Methods:<p>Patients with newly diagnosed RAS wild-type, chemotherapy-naïve mCRC, both right- left-sided,...
<p>Supplementary figures</p>
<p>Supplementary methods and data</p>
Purpose To assess tolerance and efficacy of preoperative treatment with uracil/tegafur radiotherapy (RT) followed by surgery postoperative flurouracil (FU)/leucovorin (LV) in patients rectal cancer. Patients Methods (n = 94) potentially resectable tumors, ultrasound at stages T2N+ 4), T3 77), T4 13) were treated UFT (400 mg/m 2 /d, 5 days a week for weeks) concomitant RT to the pelvis (45 Gy; 1.8 Gy/d over weeks). underwent 6 weeks later four cycles FU/LV. Primary end points included...
Background In the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent or XELOX until disease progression. An additional retrospective analysis was performed define prognostic value tumour KRAS status on progression-free survival (PFS), overall (OS) response rates. Methodology/Principal Findings data (tumour type mutation) collected questionnaire...
Abstract Background Immune check-point blockade (ICB) has shown clinical benefit in mismatch repair-deficient/microsatellite instability high metastatic colorectal cancer (mCRC) but not repair-proficient/microsatellite stable patients. Cancer vaccines with autologous dendritic cells (ADC) could be a complementary therapeutic approach to ICB as this combination the potential achieve synergistic effects. Methods This was Phase I/II multicentric study translational sub-studies, evaluate safety,...
Abstract Purpose: Peposertib—an orally administered DNA-dependent protein kinase inhibitor—has shown potent radiosensitization in preclinical models. This dose-escalation study (NCT03770689) aimed to define the maximum tolerated dose (MTD) and recommended phase II (RP2D) of peposertib plus capecitabine-based chemoradiotherapy (CRT) assessed its safety efficacy locally advanced rectal cancer. Patients Methods: were treated for 5 5.5 weeks with 50- 250-mg once daily, capecitabine 825 mg/m2...
Abstract Purpose: Preoperative chemoradiotherapy (CRT) is the treatment of choice for rectal cancer (RC), but half patients do not respond, suffer unnecessary toxicities, and surgery delays. We aimed to develop a model that could predict clinically meaningful response CRT by using formalin-fixed paraffin-embedded (FFPE) biopsies. Experimental Design: first carried out an exploratory screening candidate genes SAGE technology evaluate dynamic changes in RC transcriptome selected refractory...
Abstract Background The results of the Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD)-1402 phase II randomized trial suggested that adding aflibercept to modified fluorouracil, oxaliplatin, and leucovorin (mFOLFOX6) induction, followed by chemoradiation surgery, could increase pathological complete response (pCR) rate in patients with high-risk, locally advanced rectal cancer. Here we update up 3 years follow-up evaluate predictive value consensus molecular subtypes identified...